A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with advanced solid tumours

por Lassen, U, Nielsen, D L, Sørensen, M, Winstedt, L, Niskanen, T, Stenberg, Y, Pakola, S, Stassen, J-M, Glazer, S
Publicado 2012